Clinical Trials · NCT03790865
Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome
- Phase
- Phase 2/Phase 3
- Recruitment status
- Terminated
- Sponsor
- Millendo Therapeutics SAS
- Enrollment
- 158
- Start date
- Mar 2019
- Locations
- 37 sites, 8 countries
- Primary endpoint
- Change in Hyperphagia and Food-related Behaviors (Hyperphagia Questionnaire for Clinical Trials; HQ-CT)